BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//XIMA Media GmbH//xima_typo3_calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:entry-308@www.dkfz.de
DTSTAMP:20260929T145437Z
DTSTART:20250328T113000Z
DTEND:20250328T120000Z
SUMMARY:Cancer Core Europe (CCE) Lecture - Insights into the heterogeneity 
 of ER-positive breast cancer – late risk of metastatic recurrence & endo
 crine treatment benefit
DESCRIPTION:Friday\, March 28 - Time: 13:30 - 14:30 CET Join Zoom Meeting h
 ttps://ki-se.zoom.us/j/66629524056 Meeting ID: 666 2952 4056 Abstract Brea
 st cancer (BC) is a heterogeneous disease with the main fundamental differ
 ence being whether the tumour is hormone-sensitive or not\, i.e. oestrogen
  receptor-positive (ER+) or negative (ER-). A unique feature of ER+ BC is 
 the long-term risk of metastatic recurrence decades after initial diagnosi
 s\, and half or more of all BC metastases in this patient group will be di
 agnosed LATE i.e. beyond 5 - 10 years after diagnosis as shown by us and o
 thers [Johansson & Lindström et al\, JCO 2022\; Richman & Dowsett\, Nat R
 ev Clin Oncol 2019\; Yu & Lindström et al\, JAMA Oncology 2019\; Pan et a
 l\, NEJM 2017]. The factors underlying late risk of metastatic recurrence 
 remain poorly understood. Current research is mainly focused on early risk
 \, partly due to the lack of tumour samples from patients with complete lo
 ngterm follow-up. Late risk is clinically important in particular for youn
 ger premenopausal patients with a long post cancer life expectancy\, but a
 lso decades of fear about disease recurrence. Young premenopausal women wi
 th BC have a worse prognosis as compared to postmenopausal women\, and men
 opausal status itself has been suggested to be an independent risk factor 
 related to the hormonal milieu. My research focus is on longterm risk of m
 etastatic disease\, and how risk and endocrine treatment benefit is influe
 nced by menopausal status and tumour biology including standard tumour mar
 kers\, intra-tumour heterogeneity\, and tumour microenvironment using uniq
 ue clinical trials with complete longterm follow-up. What is Cancer Core E
 urope (CCE)? Cancer Core Europe is a consortium of seven leading cancer ce
 ntres (www.cancercoreeurope.eu). CCEs members are driven by a strong will 
 to reshape the cancer research model to ultimately increase the European U
 nion’s competitiveness as a place to conduct cutting-edge research that
 ’s translated to the clinic to deliver more personalized medicine. What 
 is the content and aim of the CCE Lecture? The CCE Lecture serie is a CCE-
 internal event\, which educates and informs about state of the art researc
 h within the seven centers and is aimed to increase awareness among partne
 rs about each other’s activities and potential for collaboration.
LOCATION:Online
URL:https://www.dkfz.de/en/news/events/details/54-cancer-core-europe-cce-le
 cture-insights-into-the-heterogeneity-of-er-positive-breast-cancer-late-ri
 sk-of-metastatic-recurrence-endocrine-treatment-benefit/a308
CATEGORIES:Vorträge und Seminare
STATUS:CONFIRMED
SEQUENCE:1790690401
LAST-MODIFIED:20260929T140001Z
END:VEVENT
END:VCALENDAR